Effects of beta blockers on central arterial pressure and vascular stiffness - NA

• Conditions: Patients with hypertension and/or ischemic heart disease

• Registration Number: EUCTR2008-001509-40-HU
• Lead Sponsor: Hungarian Kidney Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07-24
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

- 18-70 yrs
- patients with hypertension and/or ischemic heart disease to whom treatment with an oral beta-blocker is suggested

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- treatment with a beta-blocking agent within 3 months
- being allergic to any of the components of the drugs
- II-III degree AV-block
- sick sinus syndrome
- severe chronic obstructive pulmonary disease, asthma or bronchospasm
- severe peripheral arterial disease
- uncompensated heart failure
- untreated pheochromocytoma
- treatment with a MAO-inhibitor
- pregnancy or lactation
- severe liver damage or liver failure
- psoriasis
- severe hypertension (>180/110 mmHg)
- atrial fibrillation
- lack of informed consent
- poor compliance

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The primary aim of the present study is to determine how nebivolol, carvedilol and metoprolol affects central arterial pressure and aortic pulse wave velocity ;Secondary Objective: The secondary aim of the present study is to compare the efficacy of nebivolol, carvedilol and metoprolol in reducing central arterial pressure and aortic pulse wave velocity.;Primary end point(s): Primary end-points are changes in central arterial systolic pressure and aortic pulse wave velocity after 3 months of treatment.